AOA Dx Submits CLIA Application and Opens Waitlist for Omira™ OC, the Blood Test Built for Women With Ovarian Cancer Symptoms

With its CLIA application submitted, AOA Dx is preparing to launch Omira OC and invites  patients, clinicians and partners to join the waitlist

Denver, CO, November 16, 2026. AOA Dx today announced a key commercial milestone: it has submitted its CLIA application for its Denver laboratory and opened a waitlist for Omira™ OC, a blood test for the early detection of ovarian cancer in women with symptoms. The company expects its CLIA certificate of registration soon, and Omira OC launches in 2027.

Ovarian cancer symptoms are vague and overlap with many other conditions, often delaying diagnosis until a late stage, when the chances of survival are much lower. Omira OC was built for the moment a woman first presents with vague abdominal symptoms to her provider, before a mass has been identified. Today, that visit often begins a long and winding diagnostic odyssey with repeat appointments, GI workups, imaging and referrals to different specialists, with diagnosis taking about nine months on average. Omira OC gives the clinician a blood test at that first visit to triage the patient, so they can decide on the right next step sooner and get women who may have ovarian cancer to the right care faster. 

OMIRA OC is the first test from AOA Dx’s multi-omic platform, which runs on clinical-grade mass spectrometry designed to scale across oncology. CLIA, the Clinical Laboratory Improvement Amendments, is the federal standard a laboratory must meet to run patient tests and return results to a clinician. By submitting its application, AOA Dx demonstrates its laboratory and the systems that will run Omira OC are in place for launch, bringing the test that much closer to patients and providers. 

“We started AOA Dx to give women an answer when they need it most, not after months of waiting and circling the healthcare system,” said Oriana Papin-Zoghbi, CEO and Co-Founder of AOA Dx. “Omira OC was built on symptomatic women, the exact women we are here to serve, and designed for the moment before a mass is eventually found. Submitting our CLIA application brings that test closer to them.”

As AOA Dx approaches its official launch, it is opening a waitlist so interested parties can be the first to hear when Omira OC becomes available. Patients and caregivers can sign up to be the first to hear more about Omira OC. Clinicians can register their interest in offering the test to symptomatic patients in their practice. Partners can indicate their interest in offering Omira OC as part of their services. Everyone on the waitlist will hear first when Omira OC is ready to order, with updates on launch timing and how ordering will work. Omira OC can only be ordered by a clinician. 

“A woman with vague abdominal symptoms deserves a clear next step at her very first visit,” said Chris Roberts, Chief Product Officer of AOA Dx. “OMIRA OC was built for that moment. Launch volume will be limited, so we’re prioritizing everyone on the waitlist. If you want to offer this test to your patients, sign up now.”

About AOA Dx

AOA Dx is a biotechnology company developing a multi-omics liquid biopsy platform for earlier cancer detection. Its lead test, OMIRA™ OC, is being developed to improve ovarian cancer diagnosis in women experiencing symptoms. The company’s broader platform combines lipid, metabolite, and protein biomarkers to identify cancer-associated biological signals and translate them into scalable diagnostic tests.

Learn more at www.aoadx.com.

Media Contact:
Ariel Kramer

ariel@klovercommunications.com 

SHARE

Facebook
Twitter
Reddit
LinkedIn
Email